Table 3.
Adverse Clinical Outcomesa by Medicaid Status in ORBIT‐AF
| Outcome | No. of Events: Non‐Medicaid (p‐years) | No. of Events Non‐Medicaid (p‐years) | Unadjusted Event Rate per 100 Patient Years | Unadjusted HR (95% CI) | Medicaid vs Non‐Medicaid | Adjusted P Value | ||
|---|---|---|---|---|---|---|---|---|
| Non‐Medicaid | Medicaid | Unadjusted P Value | Adjusted HRb (95% CI) | |||||
| All‐cause mortality | 1146 (20 585) | 61 (890) | 5.6 | 6.9 | 1.25 (0.98, 1.60) | 0.07 | 0.97 (0.75, 1.25) | 0.80 |
| Stroke/systemic embolism | 201 (20 439) | 13 (883) | 1.0 | 1.5 | 1.51 (0.90, 2.54) | 0.12 | 1.05 (0.63, 1.76) | 0.85 |
| Major bleeding | 755 (19 791) | 36 (846) | 3.8 | 4.3 | 1.11 (0.75, 1.65) | 0.60 | 0.97 (0.67, 1.38) | 0.85 |
ORBIT‐AF indicates Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
Over 2 years of follow‐up.
Adjusted models included age, race, sex, smoking, cancer, hypertension, osteoporosis/hip fracture, diabetes, hypothyroidism, gastrointestinal bleed, obstructive sleep apnea, insufficient kidney function, hyperlipidemia, anemia, cognitive impairment/dementia, frailty, coronary artery disease, chronic obstructive pulmonary disease, alcohol or drug abuse, peripheral vascular disease, sinus node dysfunction, stroke/transient ischemic attack, congestive heart failure, valvular disease, heart rate, blood pressure, body mass index, left atrial diameter, type of atrial fibrillation (AF), past cardioversions, past antiarrhythmic drugs, past AF interventional therapy, and functional status.